Articles related to BIOMARKERS

Advanced biological aging, as measured by clinical biomarkers, increases one’s risk for dementia or stroke, despite adjustment for disease-specific risk factors. This finding underscores the potential of biological age as a predictor of neurological health.

The recent study from CTAD 2023 has demonstrated the potential of p-tau217 as a promising biomarker for preclinical Alzheimer’s disease. This finding could significantly enhance our ability to detect Alzheimer’s at its earliest stages and initiate timely interventions.

Discover how Labcorp’s new ATN Profile can revolutionize your approach to diagnosing Alzheimer’s disease.

Don’t miss this crucial update on how biomarker-guided first-line treatment can substantially improve survival rates in advanced NSCLC patients.

Discover how MPO testing can offer a more comprehensive understanding of your patients’ health risks, including mortality beyond cardiovascular disease.

Discover how retinal assessments could offer a new diagnostic and treatment frontier in Parkinson’s disease, as recent findings demonstrate significant retinal degeneration correlated with disease progression.